KROS-201 / Kairos Pharma - LARVOL DELTA

Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Jeremy Rudnick, M.D | N=10 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Jeremy Rudnick, M.D | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2027

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Jeremy Rudnick, M.D | Trial completion date: Jun 2025 ➔ Dec 2026 | Trial primary completion date: Jun 2023 ➔ Dec 2025

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

Kairos Pharma Receives FDA Approval of Investigational New Drug (IND) Application for Its Phase 1 Clinical Trial of KROS 201 for the Treatment of Glioblastoma; Announces New Patent for KROS 401 (PRNewswire) - "Kairos Pharma...announced that its activated T cell therapy, KROS 201, has received FDA approval to proceed with a Phase 1 clinical trial in patients with recurrent glioblastoma, a type of brain cancer. The phase I trial is sponsored by Kairos Pharma and will be conducted at Cedars Sinai Medical Center in Los Angeles....A Phase 1 trial of ENV105 with Tagrisso (AstraZeneca) for lung cancer is planned to start in 2022....New patent covers the method of treating fibrosis and certain forms of cancer, the composition of matter, and administering a therapy using KROS-401."

IND • New P1 trial • Patent • Brain Cancer • Glioblastoma • Lung Cancer • Oncology • Solid Tumor

Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Jeremy Rudnick, M.D

New P1 trial • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • CD133 • HER-2 • IL13RA2